[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,885,798
  • Shares Outstanding, K 107,593
  • Annual Sales, $ 0 K
  • Annual Income, $ -167,800 K
  • EBIT $ -200 M
  • EBITDA $ -205 M
  • 60-Month Beta 0.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.54

Options Overview Details

View History
  • Implied Volatility 62.82% (+2.71%)
  • Historical Volatility 78.02%
  • IV Percentile 5%
  • IV Rank 5.84%
  • IV High 270.13% on 10/22/25
  • IV Low 49.96% on 01/14/26
  • Expected Move (DTE 5) 3.15 (6.93%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 83
  • Volume Avg (30-Day) 449
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 9,461
  • Open Int (30-Day) 10,710
  • Expected Range 42.27 to 48.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.48
  • Number of Estimates 7
  • High Estimate $-0.42
  • Low Estimate $-0.58
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) -41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.84 +47.24%
on 06/16/26
48.40 -6.18%
on 07/09/26
+12.49 (+37.94%)
since 06/10/26
3-Month
30.12 +50.76%
on 05/01/26
48.40 -6.18%
on 07/09/26
+12.59 (+38.36%)
since 04/10/26
52-Week
12.30 +269.19%
on 08/11/25
48.40 -6.18%
on 07/09/26
+31.54 (+227.40%)
since 07/10/25

Most Recent Stories

More News
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 45.41 (-6.08%)
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% –

EWTX : 45.41 (-6.08%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 45.41 (-6.08%)
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones —

EWTX : 45.41 (-6.08%)
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

BOULDER, Colo. , May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present...

EWTX : 45.41 (-6.08%)
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

–   Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up –

EWTX : 45.41 (-6.08%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 45.41 (-6.08%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 45.41 (-6.08%)
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

–The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies –

EWTX : 45.41 (-6.08%)
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

BOULDER, Colo. , March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present...

EWTX : 45.41 (-6.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

See More

Key Turning Points

3rd Resistance Point 52.08
2nd Resistance Point 50.11
1st Resistance Point 47.76
Last Price 45.41
1st Support Level 43.44
2nd Support Level 41.46
3rd Support Level 39.11

See More

52-Week High 48.40
Last Price 45.41
Fibonacci 61.8% 34.61
Fibonacci 50% 30.35
Fibonacci 38.2% 26.09
52-Week Low 12.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.